Status:
UNKNOWN
Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia
Lead Sponsor:
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Conditions:
2019 Novel Coronavirus Pneumonia
Eligibility:
All Genders
Up to 100 years
Brief Summary
the investigators conduct a randomized, open-label trial to evaluate and compare the safety and efficacy of Xiyanping injection in patients with 2019-nCoV pneumonia.
Eligibility Criteria
Inclusion
- Laboratory examination (RT-PCR) confirms the infection 2019-nCoV, which meets the diagnostic criteria for pneumonia (common type) in the New Coronavirus Infection Pneumonia Diagnosis and Treatment Program (Trial Version 6);
- The patient has a complete hospitalization record that can be used for research.
Exclusion
- \-
- Subjects who meet any of the following criteria cannot be enrolled:
- Suffering from diseases that need to be distinguished from pneumonia infected with new coronavirus, such as tuberculosis, bacterial or viral pneumonia other than new coronavirus pneumonia, hospital-acquired pneumonia, and other pathogenic microorganisms pneumonia;
- People with basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory tract malformations, abnormal lung development, aspiration pneumonia, and lung malignant tumors;
- According to the judgment of the investigator, the previous or current disease may affect the patient's participation in the trial or the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; presently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or blood system, or splenectomy, organ transplantation, etc;
- Pneumonia diagnosed with severe, critically re-associated coronavirus infection or requiring mechanical ventilation or systemic anti-hormonal therapy;
- Used Chinese patent medicines with similar efficacy as Xiyanping injection during the treatment.
- The investigator judges that the relevant test or data is missing during the treatment process, which affects the research evaluation or analyst.
Key Trial Info
Start Date :
May 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 14 2021
Estimated Enrollment :
426 Patients enrolled
Trial Details
Trial ID
NCT04275388
Start Date
May 15 2020
End Date
December 14 2021
Last Update
May 20 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.